On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion.
Collecting what is known about reading a combination trial in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find.
This is a summary rather than new work, and I have attributed each part to where I found it.
Injection-site tolerability is reported more often for this compound than for the incretins, and it is worth reading the trial reports rather than the summaries on that point specifically.
If the premise is wrong, everything after it is decoration.
Post #2 is right about the mechanism and I think understates the practical bit.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
Worth separating two things that the opening post runs together.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
Bookmarking this. I will come back when I have something worth adding.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because a question about…
|
2 | 41k | 14mo | |
|
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
|
+48 | 53 | 31k | 13mo |
|
About the Cagrilintide & amylin analogues category
Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 1.8k | 11mo | |
|
Nausea profile of amylin analogues compared with GLP-1 agonists
Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin nausea profile of…
|
+70 | 76 | 3k | 4mo |
|
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins
Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. A question about Amylin and gastric emptying that I think has a…
|
+21 | 25 | 44k | 5mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post,…
|
2 | 103 | 17mo | |
|
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold?
The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. A question about…
|
+103 | 115 | 24k | 10mo |
|
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
|
+115 | 125 | 30k | 2y |
|
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. A methods question rather than a substantive one, about Criticising…
|
+16 | 20 | 61k | 11mo |